Precision Biosciences Inc (DTIL)

$10.17

+0.22

(+2.21%)▲

Market is closed - opens 7 PM, 26 Jul 2024

Performance

  • $9.90
    $10.38
    $10.17
    downward going graph

    2.65%

    Downside

    Day's Volatility :4.62%

    Upside

    2.02%

    downward going graph
  • $8.25
    $19.43
    $10.17
    downward going graph

    18.88%

    Downside

    52 Weeks Volatility :57.54%

    Upside

    47.66%

    downward going graph

Returns

PeriodPrecision Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
8.42%
6.5%
0.0%
6 Months
-6.25%
7.1%
0.0%
1 Year
-42.05%
9.8%
0.0%
3 Years
-96.64%
14.2%
-20.2%

Highlights

Market Capitalization
68.9M
Book Value
$5.38
Earnings Per Share (EPS)
-5.61
Wall Street Target Price
33.0
Profit Margin
-48.1%
Operating Margin TTM
-23.81%
Return On Assets TTM
-11.1%
Return On Equity TTM
-51.66%
Revenue TTM
57.5M
Revenue Per Share TTM
13.77
Quarterly Revenue Growth YOY
100.29999999999998%
Gross Profit TTM
25.1M
EBITDA
-28.6M
Diluted Eps TTM
-5.61
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.14
EPS Estimate Next Year
-5.58
EPS Estimate Current Quarter
-1.91
EPS Estimate Next Quarter
-1.82

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Precision Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 224.48%

Current $10.17
Target $33.00

Company Financials

FY18Y/Y Change
Revenue
10.9M
↑ 67.84%
Net Income
-46.0M
↑ 118.16%
Net Profit Margin
-423.02%
↓ 97.57%
FY19Y/Y Change
Revenue
22.2M
↑ 104.34%
Net Income
-83.3M
↑ 80.94%
Net Profit Margin
-374.59%
↑ 48.43%
FY20Y/Y Change
Revenue
24.3M
↑ 9.2%
Net Income
-109.0M
↑ 30.86%
Net Profit Margin
-448.86%
↓ 74.27%
FY21Y/Y Change
Revenue
115.5M
↑ 375.72%
Net Income
-30.9M
↓ 71.64%
Net Profit Margin
-26.76%
↑ 422.1%
FY22Y/Y Change
Revenue
25.1M
↓ 78.28%
Net Income
-122.9M
↑ 297.53%
Net Profit Margin
-489.71%
↓ 462.95%
FY23Y/Y Change
Revenue
48.7M
↑ 94.15%
Net Income
-69.8M
↓ 43.24%
Net Profit Margin
-143.18%
↑ 346.53%
Q4 FY22Q/Q Change
Revenue
10.6M
↑ 43.94%
Net Income
-36.5M
↑ 46.17%
Net Profit Margin
-344.28%
↓ 5.26%
Q1 FY23Q/Q Change
Revenue
8.8M
↓ 17.15%
Net Income
-23.6M
↓ 35.43%
Net Profit Margin
-268.31%
↑ 75.97%
Q2 FY23Q/Q Change
Revenue
19.8M
↑ 125.39%
Net Income
-11.9M
↓ 49.52%
Net Profit Margin
-60.09%
↑ 208.22%
Q3 FY23Q/Q Change
Revenue
13.1M
↓ 33.7%
Net Income
-8.1M
↓ 32.06%
Net Profit Margin
-61.58%
↓ 1.49%
Q4 FY23Q/Q Change
Revenue
7.0M
↓ 46.36%
Net Income
-16.3M
↑ 101.62%
Net Profit Margin
-231.44%
↓ 169.86%
Q1 FY24Q/Q Change
Revenue
17.6M
↑ 149.84%
Net Income
8.6M
↓ 152.72%
Net Profit Margin
48.84%
↑ 280.28%
FY18Y/Y Change
Total Assets
138.6M
↑ 90.69%
Total Liabilities
98.6M
↓ 0.41%
FY19Y/Y Change
Total Assets
235.2M
↑ 69.72%
Total Liabilities
96.9M
↓ 1.74%
FY20Y/Y Change
Total Assets
150.2M
↓ 36.17%
Total Liabilities
105.7M
↑ 9.09%
FY21Y/Y Change
Total Assets
211.5M
↑ 40.85%
Total Liabilities
120.3M
↑ 13.81%
FY22Y/Y Change
Total Assets
238.2M
↑ 12.61%
Total Liabilities
177.7M
↑ 47.71%
FY23Y/Y Change
Total Assets
159.8M
↓ 32.91%
Total Liabilities
140.9M
↓ 20.71%
Q4 FY22Q/Q Change
Total Assets
238.2M
↓ 12.35%
Total Liabilities
177.7M
↓ 5.13%
Q1 FY23Q/Q Change
Total Assets
204.5M
↓ 14.14%
Total Liabilities
164.3M
↓ 7.55%
Q2 FY23Q/Q Change
Total Assets
181.7M
↓ 11.15%
Total Liabilities
147.7M
↓ 10.14%
Q3 FY23Q/Q Change
Total Assets
164.3M
↓ 9.55%
Total Liabilities
135.3M
↓ 8.38%
Q4 FY23Q/Q Change
Total Assets
159.8M
↓ 2.78%
Total Liabilities
140.9M
↑ 4.17%
Q1 FY24Q/Q Change
Total Assets
184.7M
↑ 15.62%
Total Liabilities
147.5M
↑ 4.69%
FY18Y/Y Change
Operating Cash Flow
-51.7M
↑ 114.01%
Investing Cash Flow
-15.7M
↑ 184.01%
Financing Cash Flow
107.8M
↓ 11602.35%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 37.3%
Investing Cash Flow
-24.7M
↑ 57.48%
Financing Cash Flow
173.4M
↑ 60.86%
FY20Y/Y Change
Operating Cash Flow
-87.4M
↑ 23.05%
Investing Cash Flow
-5.0M
↓ 79.6%
Financing Cash Flow
1.3M
↓ 99.23%
FY21Y/Y Change
Operating Cash Flow
-10.9M
↓ 87.58%
Investing Cash Flow
-5.8M
↑ 15.34%
Financing Cash Flow
70.5M
↑ 5206.32%
FY22Y/Y Change
Operating Cash Flow
-45.8M
↑ 321.57%
Investing Cash Flow
-3.3M
↓ 42.81%
Financing Cash Flow
95.0M
↑ 34.69%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.8M
↓ 174.84%
Investing Cash Flow
-632.0K
↓ 42.02%
Financing Cash Flow
-5.0K
↓ 97.22%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.5M
↑ 44.05%
Investing Cash Flow
-721.0K
↑ 14.08%
Financing Cash Flow
741.0K
↓ 14920.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-21.1M
↓ 32.83%
Investing Cash Flow
-1.1M
↑ 46.46%
Financing Cash Flow
1.9M
↑ 149.93%

Technicals Summary

Sell

Neutral

Buy

Precision Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Precision Biosciences Inc
Precision Biosciences Inc
5.17%
-6.25%
-42.05%
-96.64%
-97.38%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Precision Biosciences Inc
Precision Biosciences Inc
NA
NA
NA
-5.14
-0.52
-0.11
NA
5.38
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Precision Biosciences Inc
Precision Biosciences Inc
Buy
$68.9M
-97.38%
NA
-48.1%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Precision Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 7.03M → 17.58M (in $), with an average increase of 60.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -16.28M → 8.58M (in $), with an average increase of 289.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 103.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 283.1%

Institutional Holdings

  • TANG CAPITAL MANAGEMENT LLC

    8.51%

  • HHG PLC

    8.27%

  • Perceptive Advisors LLC

    6.94%

  • Aquilo Capital Management, LLC

    5.57%

  • Vanguard Group Inc

    3.77%

  • Alyeska Investment Group, L.P.

    3.61%

Company Information

precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.

Organization
Precision Biosciences Inc
Employees
109
CEO
Mr. Michael Amoroso
Industry
Biotechnology

Discover More

FAQs